VNRX · Volitionrx Ltd
Substantial doubt about the company's ability to continue as a going concern.
“The Company concluded that these plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
2 customers — 38% of receivables (December 31, 2025)
“At December 31, 2025 the two largest customer balances represented over 38% of the total outstanding accounts receivable balance.”
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2024-12-31 | $0 | 10-K, filed 2025-03-31 |
| 2023-12-31 | $31,772 | 10-K, filed 2025-03-31 |
| 2022-12-31 | $0 | 10-K, filed 2024-03-25 |